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ABSTRACT 
The protective effect of a combined rotavirus/enterotoxigenic E. coli K99 vac­
cine against naturally occurring neonatal diarrhoea was evaluated in two dairy and 
two beef herds. Before vaccination, frequency of diarrhoea in these herds was 46% up 
to 60% with losses of 7% to 20%. After vaccination of pregnant cows and heifers 
mild diarrhoea occurred in 14% to 20% of their calves, one out of 144 calves died with 
enteric symptoms. In 13 out of 26 calves of nonvaccinated controls where diarrhoea 
was noted, one of them died. K99-positive enterotoxigenic E. coli were not detected in 
any of the faeces tested. Rotavirus was found in one of the beef herds. 
Neonatal diarrhoea is still one of the most serious problems in calf-
breeding, especially in its modern form with large numbers of animals. The eco­
nomic losses due to diarrhoeal disease during the first two weeks of life are enor­
mous. They result from the loss of calves, retarded growth rates and — last but 
not least — from the cost of the treatment of affected animals. 
A number of infectious agents can be recovered from the faeces of such 
diseased calves, including viruses, e.g. rota-, corona- or parvoviruses, bacteria 
like enterotoxigenic E. coli and protozooa, e.g. Cryptosporidia (8). Recent results 
indicate that mixed infections with two or more of these agents are the rule rather 
than the exception. Furthermore, it can be supposed that the severe forms of 
diarrhoeal disease seen in the field are always caused by mixed infections. Evi­
dence from experimental infections confirms this hypothesis. The clinical course 
of the disease after mixed infection with rotavirus and enterotoxigenic E. coli or 
Coronavirus is more severe and results in higher mortality rates than monoinfec­
tions usually do. For instance, it has been shown that colostrum-deprived calves 
survived an infection with 108 enterotoxigenic E. coli whereas after mixed infec­
tion with rotavirus and the same doses E. coli, all of the animals died (15). Fur­
ther evidence comes from other investigations (21, 17) in colostrum-deprived and 
conventional calves. The results indicate that adhesion, colonization and growth 
of enterotoxigenic E. coli in the small intestine is enhanced by a preceeding or 
simultaneous infection with rotaviruses. Moreover it seems that such mixed 
infections cause severe disease even in older calves. Taken together, these data 
238 W. Eichhorn et al. 
indicate a probable synergism of the pathogens involved, although up to now a 
possible interference cannot be excluded. However, for the development of an 
effective immunoprophylaxis, it can be deduced that only combined vaccines 
containing two or more of the pathogens described will be successful. 
Former recommendations for the prophylaxis of neonatal enteric disease 
included the improvement of sanitary conditions, feeding of preserved colostrum 
for at least one week and active local immunization or newborn calves (3). This 
strategy, however, proved to be unsatisfactory. Early publications on the effect 
of a commercially produced rotaviral vaccine seemed to be promising (19), but 
following studies could not confirm these results (1, 9, 12). 
On the other hand, oral immunization against enterotoxigenic E. coli is 
reported to be very effective (7). One of the draw-backs of this kind of vaccine is 
its strict O-antigen specifity. Considering the broad spectrum of O-antigens of 
enterotoxigenic E. coli, it is obvious that a specific vaccine must be prepared for 
each herd. 
Finally, it seems to be impossible to achieve any amelioration of the hygie­
nic conditions in the majority of the farms and most of the farmers usually 
neglect the advice to preserve colostrum and feed it to the calves for at least one 
week. 
Because of this failure of the hitherto recommended prophylactic measu­
res, interest is now focussed on passive immunization of calves by vaccinations of 
their dams (3, 14, 16, 22). 
We have developed a combined rotavirus/enterotoxigenic E. coli K99 vac­
cine. This report describes its effects in the field. 
MATERIALS AND METHODS 
1) Vaccine 
a) Rotavirus 
The bovine rotavirus isolate Munich V 1005/78 was grown in Ma 104 cells in the presence of 
trypsin (50 μg/ml) and EDTA (20 μg/ml) in roller bottles (4). When about 90% of the cell showed a 
cytopathic effect — usually after 24 hours — the virus was harvested by freezing, thawing and low 
speed centrifugation. The supernatants exhibited a TCID 5 0 of at least 10 6· 5 and in the rotavirus anti­
gen ELISA titres between 1:32 and 1:64. They were mixed with 1 °/o of a monospecific hyperimmune 
serum against bovine rotavirus and left at 4°C overnight. After this treatment no activity could be 
detected in the rotavirus antigen ELISA, whereas in the rotavirus antibody ELISA, titres between 
1:16 and 1:32 were determined. In preceeding experiments we have shown that antibody complexed 
rotavirus together with adjuvants elicits higher antibody titres in the milk of vaccinated animals than 
uncomplexed rotavirus together with the same adjuvants (Figure 1). 
b) E. col i 
The E. coli K99 pilus-antigen was prepared according to a described method (18) with minor 
modifications. The E. coli strains 0 101 K99 was incubated for 16 hours on minca-plates, suspended 
in saline and homogenized. After high speed centrifugation (17,000 rpm, 30 min) merthiolate 
(0.01 %) was added to the supernatant. The K99 antigen was titrated by hemagglutination with horse 
erythrocytes in the presence of 1 °7o mannose at 4°C. 
One vaccine dose, composed of 512 hemagglutinating units of the K99 antigen and 10 ml of 
the rotavirus antigen-antibody complexes, was mixed with 5 ml aluminium hydroxid — prediluted 
1:8 — and left overnight at 4°C. Finally, 4 ml adjuvants PD (Philip Duphar, Amsterdam) were 
added and after vigorous shaking the vaccine was ready for use. 
Vaccination of cows to protect calves 239 
3 -
A n t i b o d y 
2-
1-
1 7 14 21 
Days after calving 
Fig. 1. Rotavirus antibody titres (as measured in the ELISA) in colostrum and milk from cows and 
heifers vaccinated with different preparations. • Control animals (n = 10). + Adjuvants PD 
(n = 9). * Rotavirus and adjuvants (n = 3). 0 Antibody complexed rotavirus and adjuvants 
(n = 23). 
2) Animals 
Pregnant cows and heifers — 35 in the two dairy herds and 135 in the two beef herds — were 
vaccinated twice. They were immunized first at the end of lactation, i.e. about six weeks before the 
calculated date of parturition and boostered as soon as possible after calving, i.e. in the first two 
days. The placebo was given to every fifth animal. Between 1979 and 1981 rotavirus and/or entero­
toxigenic E. coli had been detected in all four herds. 
3) Isolation procedures 
Faecal material was collected from both healthy and diseased animals. The samples were tes­
ted for rotaviral antigen in the ELISA (2) and inoculated onto Ma 104 cells after treatment with acety-
lated trypsin as described by others (4, 23). 
Hemagglutinating faecal samples were tested for the presence of bovine coronaviruses by 
hemagglutination-inhibition using specific antisera. 
Bacteriological examinations were performed according to standard procedures. E. coli isola­
tes with hemagglutinating activity in the presence of mannose were tested for K99 antigen (8) and 
enterotoxin in the baby mouse test (11). 
RESULTS 
Table I summarizes the clinical data from the dairy herds A and Β in winter 
1980/81 and in winter 1981/82 when the cows were immunized. Vaccination 
reduced the percentage of calves with diarrhoea from 50% up to 60% to 15.4% 
and 20%, respectively. In contrast, five out of seven control calves displayed 
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signs of disease. The one animal from herd Β that died with enteric symptoms 
had been very weak from birth and had ingested only small amounts of colos­
trum and milk. The other animals — both vaccinates and controls — showed 
only soft faeces whereas severe forms of the disease with liquid faeces and dehy­
dration were not seen. 
Table I . Frequency of diarrhoea and deaths due to enteric disease in winter 1980/81 
and 1981/82 in the dairy herds A and Β 
Herd A Herd Β 
Calves born Diarrhoea Calves died Calves born Diarrhoea Calves died 
1980/81 20 10 (50%) 4(20%) 30 24 (60%) 4(13%) 
1981/82 
Vaccinates 13 2 (15.4%) 0 15 3 (20%) 1 (6.6%) 
Controls 4 2 (50%) 0 3 2 (66%) 0 
In none out of 39 faecal samples from herd A could rotavirus or rotavirus 
antigen be detected. Coronavirus was found for three days in the faeces of one 
affected animal. In herd B, however, four out of five diarrhoeic calves shed rota­
virus in their faeces for up to four days as demonstrated by ELISA and virus iso­
lation in cell culture. Except for the calf that died on day eleven, virus shedding 
was first seen on day six when the calves were no longer fed with the milk of their 
dams. 
In both herds, hemagglutination E. coli were detected in about one half of 
the samples but none of the isolates possessed K99 antigen or enterotoxin. Shed­
ding of E. coli did not correlate with the disease. 
In the two beef herds C and D there also had been a high incidence of neo­
natal diarrhoea in the years before vaccination. During the winter of 1979/80 
54% of the calves suffered from the disease and 7.2% died. In the winter of 
1980/81 53% of the calves from herd C and 46% in herd D were affected with 
enteric disease and 7.7% respectively 4.9% of the calves were lost. Vaccination 
of the dams reduced the frequency of diarrhoea to 14% in herd C and 17.5% in 
herd D (Table II). All the calves from vaccinated mothers survived whereas one 
Table II. Frequency of diarrhoea and deaths due to enteric disease during winter 1980/81 
and 1981/82 in the beef herds C and D 
Herd C Herd D 
Calves born Diarrhoea Calves died Calves born Diarrhoea Calves died 
1980/81 78 41 (53%) 6(7.7%) 61 28 (46%) 3(4.9%) 
1981/82 
Vaccinates.. 64 9(14%) 0 52 9 (17.3%) 0 
Controls 13 7 (53.8%) 1(7.7%) 6 2 (33%) 0 
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of the control calves died. Although the occurrence of diarrhoea in the control 
group was much higher than in vaccinated animals, in both groups only a mild 
and transient diarrhoea, with the exception for the calf that died, was noted. 
In none of the faecal samples — neither from vaccinated nor control ani­
mals — was rotavirus or Coronavirus detected. E. coli with haemagglutinating 
activity were isolated from the faeces of both healthy and affected animals, but 
none of them possessed K99 antigen or enterotoxin. 
DISCUSSION 
The development of the combined rotavirus/is. coli K99 vaccine is based 
on two recent events: first there is a series of papers demonstrating the possibility 
of prolonging the secretion of rotavirus antibodies in the milk of cows by paren­
teral immunization (6, 14, 22). Secondly, it has been shown that colostrum from 
cows vaccinated with enterotoxigenic K99 positive E. coli protects newborn cal­
ves from experimental infection (6, 10, 20). 
The protective effect of passive immunization against enteric disease by 
vaccination of the dams is strictly dependent upon the continuous feeding of milk 
from vaccinated animals for at least fourteen days. This is evident from the situa­
tion in herd B, where the calves were fed with their mothers' milk for five days 
only. After vaccination of the dams diarrhoea was still noted in 20% of the cal­
ves. In four out of five affected animals, shedding of rotavirus from day six 
onwards was demonstrated. 
In contrast, in the dairy herd B, where the calves were fed with their 
mothers' milk for fourteen days, and in the two beef herds, where the calves 
suckled their dams for months, the incidence of diarrhoea was lower (between 15 
and 17%) and none of the faecal samples contained rotaviruses. As coronaviru-
ses were detected only in the faeces of one animal and the E. coli isolates posses­
sed neither the K99 antigen nor enterotoxin, the possible importance of non­
infectious factors as a cause of mild transient diarrhoea should be taken into 
account (13). 
It is not surprising that in these herds neither rotaviruses nor enterotoxige­
nic E. coli could be recovered from the faeces of the control calves. In most of 
the herds affected with high frequency of neonatal diarrhoea, the severe forms of 
the disease are generally first seen some weeks after the calving period has begun. 
It can be supposed that during these weeks enteric pathogens are accumulating. 
If a certain threshold is exceeded the clinical course becomes severe. This accu­
mulation of pathogens can be prevented by passive immunization. As a result, 
the so called controls will not be infected either. Therefore the data from such 
controls must be handled with care. In our opinion, passive immunization of cal­
ves against enteric disease by vaccination of their dams with combined vaccines is 
a reliable way to reduce the incidence of neonatal diarrhoea. 
A larger field trial with a vaccine containing also corona- and parvovirus is 
currently in progress. 
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DISCUSSION 
KAPIKIAN: Did you compare the titers achieved with the antibody com-
plexed rotavirus with a rotavirus preparation inactivated by conventional 
methods such as formalin or heating? 
By using «inactivated» rotavirus antigen as you have, to induce rotavirus 
antibody in cows, is of particular interest in view of a recent report by Myers & 
Snodgrass in which they evaluated the ability of a US approved live, modified 
bovine (NCDV) rotavirus vaccine to induce colostral or milk antibodies in pre­
gnant cows. This vaccine was initially approved for oral administration to calves, 
later also approved as a combined vaccine with live, modified bovine Coronavirus 
for oral administration to calves and more recently also approved for administra­
tion by the IM route to the pregnant cow. The authors reported that a compari­
son of GMT in colostrum and 3 day milk in vaccinated and non-vaccinated cows 
were not significantly different. They recommended the use of inactivated anti­
gen for stimulating colostral or milk antibody in the cow for several reasons 
including the possible inhibition of viral replication by naturally occurring anti­
body in the cow. 
EICHHORN: It does not make any difference how you inactivate the 
virus; when you complex the virus it elicits higher titers than non-complexed 
virus. In our next field trial we shall use inactivated, antibody complexed virus. 
ALLEN: What kind of adjuvant did you use? 
EICHHORN: We used aluminium hydoxide and a polymer adjuvant. No 
side reactions were seen in any of the animals. 
RIJKE: Do you have an explanation for the immunogenicity of your rota­
virus antibody complexes? 
In EM we have looked at these complexes, they look like big aggregates. 
That could specifically stimulate the immune response as has been described in 
other animals. 
EICHHORN: When you look at the antibody complexed virus in the EM 
you see large clusters of virus, which are possibly more immunogenic than non-
complexed virus. It is not known whether there are other immunologic mecha­
nisms in cattle as described for laboratory animals. 
